India-based pharmaceutical company Intas Pharmaceuticals Limited announced on Saturday a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending approval of HETRONIFLY (serplulimab, approved as Hansizhuang in China) in Europe.
Serplulimab is a recombinant humanised anti-PD-1 monoclonal antibody (mAb) injection developed by Chinese biopharmaceutical company Henlius (HKG:2696). It has received orphan drug designation from the US Food and Drug Administration (FDA) and the European Commission for the treatment of Small Cell Lung Cancer (SCLC).
Intas subsidiary Accord Healthcare Ltd will commercialise the treatment across more than 30 countries in Europe.
The positive CHMP opinion was primarily based on ASTRUM-005, a randomised, double-blind, placebo-controlled international multi-centre clinical study that assessed the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy, compared with placebo plus chemotherapy as first-line treatment in patients with extensive stage SCLC.
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial